Stock comparison
ResMed
Sarepta Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
SRPT
Sarepta Therapeutics
Market cap
$1.77B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RMD | SRPT | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 40D | RMD |
| Benjamin Graham | 75B | 47D | RMD |
| Philip Fisher | 75B | 51C | RMD |
| Peter Lynch | 58C | 59C | SRPT |
| Joel Greenblatt | 47D | 7F | RMD |
| Charlie Munger | 69B | 39D | RMD |
| Terry Smith | 73B | 33F | RMD |
Side-by-side metrics
| Metric | RMD | SRPT |
|---|---|---|
| Market cap | $30.18B | $1.77B |
| P/E (TTM) | 19.6x | 31.3x |
| EV/EBIT | 17.1x | - |
| ROIC (TTM) | 19.63% | -1.53% |
| Gross margin | 61.69% | 62.39% |
| Net margin | 27.44% | 2.98% |
| Revenue CAGR 5y | 12.64% | 33.03% |
| EPS CAGR 5y | 30.73% | - |
| Debt / Equity | 0.1x | 0.7x |
| Dividend yield | 1.14% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RMD leads on
- ROIC (TTM)19.63%vs -1.53%+108%
- Dividend yield1.14%vs 0.0%+100%
- Market cap$30.18Bvs $1.77B+94%
- Net margin27.44%vs 2.98%+89%
SRPT leads on
- EV/EBIT-vs 17.1x+123%
- Revenue CAGR 5y33.03%vs 12.64%+62%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.